In addition, knowing the autoantibody profile of patients may help to predict the possible clinical syndromes that can arise and make clinicians more suspicious for the presence of interstitial lung disease, for instance, when isolated anti-Ro52/TRIM21 exists. Here, TRIM21 is linked to interstitial lung disease.